AXSOME THERAPEUTICS INC financial statements, including revenue, expenses, profit, and loss

The total revenue of 19X for the last quarter is 69.51 M EUR, and it's 7.25% higher compared to the previous quarter. The net income of Q1 24 is -63.35 M EUR.